Compare
Medicus Pharma Ltd. vs Oragenics Inc vs Korsana Biosciences, Inc. vs Lunai Bioworks Inc.
| Latest fiscal year | Medicus Pharma Ltd. MDCX | Oragenics Inc OGEN | Korsana Biosciences, Inc. KRSA | Lunai Bioworks Inc. LNAI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | n/a | n/a | $2.07M | $52.0K |
| Revenue growth (YoY) | n/a | n/a | +3.7% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | -239.8% | n/m |
| Net margin | n/a | n/a | -170.1% | n/m |
| Net income | -$47.28M | -$9.84M | -$3.53M | -$3.56M |
| EPS (Diluted) | -$2.74 | -$4.56 | -$1.11 | -$1.06 |
| Operating cash flow | -$22.78M | -$9.25M | -$3.31M | -$5.29M |
| Free cash flow | n/a | n/a | n/a | -$5.29M |
| Cash & equivalents | $8.71M | $4.40M | $3.24M | $1.71M |
| Total assets | $10.06M | $10.07M | $9.98M | $9.94M |
| Total liabilities | $10.02M | $1.79M | n/a | $18.97M |
| Shareholders' equity | $37.3K | $8.28M | $9.09M | -$9.02M |
| Return on year-end equity | n/m | -118.9% | -38.8% | n/a |
| Shares outstanding | 25.18M | 4.27M | 3.82M | 4.62M |
Revenue, most recent five fiscal years
| Fiscal year | Medicus Pharma Ltd. | Oragenics Inc | Korsana Biosciences, Inc. | Lunai Bioworks Inc. |
|---|---|---|---|---|
| Latest | n/a | $37.7K Ended 2023-12-31 | $2.07M Ended 2025-12-31 | $52.0K Ended 2026-06-30 |
| 1 year earlier | n/a | $131.5K Ended 2022-12-31 | $2.00M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $87.0K Ended 2021-12-31 | $0 Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $297.0K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $3.94M Ended 2021-12-31 | n/a |